Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Melphalan Flufenamide (Pepaxto)
Overview
Melphalan flufenamide is a first-in-class peptide-drug conjugate that links the alkylating agent melphalan to a dipeptide carrier. The dipeptide facilitates cellular uptake via aminopeptidases that are overexpressed in myeloma cells, where intracellular cleavage releases active melphalan.
Mechanism of Action
This targeted delivery aims to enhance tumor exposure while reducing systemic toxicity. The compound represents a prodrug strategy to improve the therapeutic index of cytotoxic chemotherapy.
Research Summary & Key Findings
Accelerated FDA approval was granted in February 2021 based on the single-arm HORIZON trial in relapsed/refractory multiple myeloma (ORR 29%). The confirmatory OCEAN trial subsequently showed inferior overall survival compared to standard regimens, leading to voluntary market withdrawal in October 2021. This case highlighted challenges in confirmatory trial design for accelerated approvals.
Clinical Status
Melphalan Flufenamide (Pepaxto) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Melphalan Flufenamide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Melphalan Flufenamide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Melphalan Flufenamide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Oncology
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...
View detailsBortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...
View detailsLutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...
View detailsLeuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...
View detailsNo lawful pathway today
Melphalan Flufenamide (Pepaxto) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.